航天控股(00031.HK)擬斥1082萬元參與認購新商務股權
格隆匯 7 月 30日丨航天控股(00031.HK)宣佈,於2020年7月30日,新世紀與長城工業、東方紅衞星、衞通集團和新商務訂立了增資協議,據此,新世紀以代價人民幣1082萬元認購人民幣1000萬元的註冊股本。
增資完成後,新商務將成為長城工業持有68.18%股權的附屬公司,而新世紀持有新商務的權益將由16.13%略為攤薄至15.15%。新商務將繼續以權益法入賬為聯營公司。
公告稱,新世紀自新商務在2011年成立以來一直是股東。增資協議所籌集的資金將用於新商務的營運資金,增資事宜將令公司持續地受益於航天電子採購平台系統的增長和利潤。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.